---
title: Resection of Metastatic Pancreatic Neuroendocrine Tumors After Induction System Treatment
nct_id: NCT04066322
overall_status: UNKNOWN
sponsor: Fudan University
study_type: OBSERVATIONAL
primary_condition: Neuroendocrine Tumors
countries: China
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT04066322.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT04066322"
ct_last_update_post_date: 2019-09-24
last_seen_at: "2026-05-12T07:08:53.913Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Resection of Metastatic Pancreatic Neuroendocrine Tumors After Induction System Treatment

**Official Title:** Resection of Metastatic Pancreatic Neuroendocrine Tumors After Induction System Treatment: Real World Study

**NCT ID:** [NCT04066322](https://clinicaltrials.gov/study/NCT04066322)

## Key Facts

- **Status:** UNKNOWN
- **Study Type:** OBSERVATIONAL
- **Target Enrollment:** 180
- **Lead Sponsor:** Fudan University
- **Conditions:** Neuroendocrine Tumors, Metastases, Surgery
- **Start Date:** 2019-08-25
- **Completion Date:** 2025-07-25
- **CT.gov Last Update:** 2019-09-24

## Brief Summary

This study is to evaluate the efficacy and tolerability of surgery in selecting patients who can benefit from the synchronous resection of primary pancreatic neuroendocrine tumor and liver metastasis after induction systemic treatment. The willing of participants decide who receive surgery and who will continue to receive standard systemic treatment.

## Detailed Description

system treatments of metastatic PanNET include SSA, sunitinib, mTOR inhibitor and chemotherapy. For patients achieved PR/SD after system treatment, resection of primary tumor and metastasis maybe a better way to decline tumor burden and get longer survival. this real world study is focused on this group of patients with metastatic PanNET, and to evaluate the efficacy and tolerability of surgery in selecting patients who can benefit from the synchronous resection of primary pancreatic neuroendocrine tumor and liver metastasis after induction systemic treatment.

## Eligibility

- **Minimum age:** 18 Years
- **Maximum age:** 80 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

1. Biopsy-proven neuroendocrine tumor
2. primary site in pancreas
3. Advanced disease with lymph node or distant metastases (N1, M1) cannot undergoing cytoreduction by surgery/local ablative therapy at the diagnosis
4. curative intent of all therapies possible
5. ECOG 0-2

Exclusion Criteria:

1. Undifferentiated neuroendocrine carcinoma or mixed neuroendocrine carcinoma secondary tumor
2. functioning NET or advanced carcinoid heart disease
3. part of hereditary syndrome, such as MEN1, VHL
4. do not willing to receive systemic treatment
5. diagnosed with other cancer within 5 years
```

## Arms

- **system treatment** — Patients continue to receive standard system treatment, including SSA, targeted therapy and chemotherapy.
- **system treatment and Surgery** — Patients receive synchronous resection of primary tumor and metastasis after system treatment. and treatment after surgery is based on the clinical decision.

## Interventions

- **system treatment and surgery** (PROCEDURE) — to patients with PR/SD after system treatment, investigator assess the tumor is resectable, and participants decide to receive Synchronous resection of primary tumor and metastasis. after surgery, the investigator decide further treatments.
- **system treatment** (OTHER) — to patients with PR/SD after system treatment, investigator assess the tumor is resectable, and participants decide to continue take system treatment.

## Primary Outcomes

- **progression-free survival** _(time frame: 5 years)_

## Secondary Outcomes

- **overall survival** _(time frame: 5 years)_
- **Number of Postoperative morbidity** _(time frame: Up to 90 days after operation)_
- **number of Postoperative mortality** _(time frame: Up to 90 days after operation)_

## Locations (1)

- Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center; Pancreatic Cancer Institute, Fudan University, Shanghai, Shanghai Municipality, China — _RECRUITING_

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.maxAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.department of pancreatic surgery, fudan university shanghai cancer center; pancreatic cancer institute, fudan university|shanghai|shanghai municipality|china` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT04066322.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT04066322*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*